Form 4 for REGN Regeneron Pharmaceuticals
Accepted 2021-12-10 00:00:00 ET · period of report 2021-12-08 · accession 0001883850-21-000022 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2021-12-10 | 2021-12-08 | REGN | Fenimore Christopher R. | SVP Ctrl | A - Grant | $0.00 | +1,859 | 21.4K | +10% | $0 |
| D | 2021-12-10 | 2021-12-08 | REGN | Fenimore Christopher R. | SVP Ctrl | A - Grant | $0.00 | +7,941 | 7,941 | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-12-08 | A | A | 1,859 | $0.00 | 21,392 | D | — | — | |
| 2 | Derivative | Non-Qualified Stock Option (right to buy) | 2021-12-08 | A | A | 7,941 | $0.00 | 7,941 | D | $644.54 · — to 2031-12-08 | 7,941 Common Stock | (F3) The stock option award vests in four equal annual installments, commencing one year after the date of grant. |